Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > LATEST
LATEST
-
COMMENTARY Can Japan Generic Industry Accelerate Self-Reform? MHLW Panel Debate Now in Homestretch
April 19, 2024
-
BUSINESS Renalys Aims to File Sparsentan for IgA Nephropathy in Japan in 2026
April 19, 2024
-
REGULATORY Japan Ups Efforts to Better Communicate Pricing, Regulations to Overseas: Official
April 19, 2024
-
REGULATORY MHLW Panel Sets Topics for PMD Act Amendment; Pediatrics, Drug Loss on Agenda
April 19, 2024
-
ORGANIZATION JPMA Reiterates Opposition to Off-Year Revisions towards Honebuto 2024
April 19, 2024
-
BUSINESS Fujifilm Shoots for 700 Billion Yen in Bio-CDMO Sales by FY2030
April 18, 2024
-
REGULATORY Japan Govt Sued for Lack of Information on COVID Vaccine Risks
April 18, 2024
-
BUSINESS Voydeya, High-Dose Eylea, Vyvdura and More Now Available in Japan
April 18, 2024
-
ORGANIZATION Doctors’ Lobby Objects MOF Proposal for CEA Use in Reimbursement Decisions
April 18, 2024
-
COLUMN Boosting Employee Retention in a Competitive Market
April 18, 2024
-
BUSINESS Kyowa Pharma Reveals Fudged Accelerated Stability Test of Mestinon
April 17, 2024
-
REGULATORY MOF Ramps Up Push for Use of Cost-Effectiveness Assessment in Reimbursement Decisions
April 17, 2024
-
BUSINESS Santen’s New China Plant Completed, Poised for 2027 Launch
April 17, 2024
-
BUSINESS Jardiance, Ofev Continue to Drive Boehringer’s Global Sales
April 17, 2024
-
BUSINESS Nippon Shinyaku Seeks Uptravi Use in Pediatric PAH in Japan
April 17, 2024
-
BUSINESS Lagevrio’s Smaller Tablet Version Filed in Japan: MSD
April 17, 2024
-
BUSINESS Moderna to File mRNA RSV Vaccine in Japan within 2024: Exec
April 17, 2024
-
REGULATORY PMDA Stepping Up Generic Compliance Inspections from August Approvals
April 16, 2024
-
BUSINESS 80%-Plus Doctors Seek In-Person Meetings with Reps: Lilly Survey
April 16, 2024
-
BUSINESS Meiji Reaffirms 2028 Launch Plan for New Vaccine Site as METI Grants Finalized
April 16, 2024
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…